Welcome to our dedicated page for CALCIMEDICA SEC filings (Ticker: CALC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CalciMedica, Inc. (CALC) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, clinical-stage biopharmaceutical company focused on CRAC channel inhibition therapies, CalciMedica uses its filings to report financial results, corporate actions, and material developments related to programs such as its Auxora™ clinical trials in acute kidney injury (AKI) with respiratory failure and acute pancreatitis (AP).
Key documents available through EDGAR and summarized here include Form 10-K annual reports and Form 10-Q quarterly reports, which provide detailed discussions of CalciMedica’s business, risk factors, pipeline status, and financial condition. Form 8-K current reports capture specific events such as quarterly earnings press releases, amendments to equity incentive plans approved at the annual meeting, and changes to at-the-market equity offering capacity under the company’s agreement with H.C. Wainwright & Co.
Investors can also monitor S-3 and S-8 registration statements and related exhibits that describe securities offerings and share-based compensation plans, as well as any Form 4 insider transaction reports that may be filed by directors and officers. These filings help clarify how CalciMedica finances its clinical-stage operations, including the use of at-the-market offerings and a disclosed credit facility, and how equity incentives are structured for employees and leadership.
Stock Titan enhances access to these documents with AI-powered summaries that highlight key points from lengthy filings, such as changes in cash runway commentary, updates on the KOURAGE trial, or modifications to capital-raising programs. Real-time updates from EDGAR ensure that new CalciMedica filings appear quickly, while structured views of 10-Ks, 10-Qs, 8-Ks, registration statements, and Form 4 reports allow users to focus on the specific regulatory information most relevant to their analysis of CALC.
CalciMedica, Inc. has filed a shelf registration prospectus to offer, from time to time, up to $125,000,000 of common stock, preferred stock, debt securities and/or warrants.
The filing states offerings will be made in one or more offerings with specific terms provided in prospectus supplements; sales are described as issuer offerings and proceeds are for the issuer’s general corporate purposes. The company’s common stock trades on Nasdaq under the symbol CALC (last reported sale $0.507 per share on March 2, 2026).
CalciMedica, Inc. is a clinical-stage biopharmaceutical company developing calcium release-activated calcium (CRAC) channel inhibitors, led by its intravenous candidate Auxora for acute pancreatitis and other critical inflammatory conditions. The company has never generated product revenue and discloses a history of net losses with substantial doubt about its ability to continue as a going concern without significant additional capital.
Auxora has shown encouraging Phase 2 data in acute pancreatitis, severe COVID-19 pneumonia, and pediatric asparaginase-induced pancreatic toxicity, and CalciMedica plans to finalize a pivotal program design in acute pancreatitis in the first half of 2026. A Phase 2 trial in acute kidney injury with acute hypoxemic respiratory failure (KOURAGE) was discontinued in January 2026 after a mortality imbalance, though independent reviewers did not find drug-related toxicity, and the company will discuss future development with the FDA.
CalciMedica is also advancing CM5480, an Orai1-selective CRAC inhibitor, toward an anticipated 2027 IND for pulmonary arterial hypertension and is exploring oral CRAC inhibitors in chronic inflammatory and immunologic diseases. It relies on third-party manufacturers, faces intense competition in inflammation and critical care, and highlights extensive scientific and development risks alongside potential opportunities for strategic partnerships.
CalciMedica Inc. reported a full-year 2025 net loss of
Cash, cash equivalents and short-term investments totaled
Clinically, the company reported no evidence of drug-related toxicity from the unblinded Phase 2 KOURAGE AKI trial, despite a previously disclosed mortality imbalance and trial discontinuation. Auxora is being advanced toward a pivotal acute pancreatitis program, with design expected to be finalized in the first half of 2026, and CM5480 continues preclinical development for pulmonary arterial hypertension with an IND submission anticipated in 2027.
CalciMedica Inc. (CALC) received an amended Schedule 13G from investment entities affiliated with Deerfield and James E. Flynn. The filing reports beneficial ownership of 653,253 shares of common stock, all issuable upon exercise of warrants held by Deerfield Partners, L.P.
The position represents 4.34% of CalciMedica’s common stock. All reporting persons disclose zero sole voting or dispositive power and shared voting and dispositive power over the same 653,253 shares. They also certify the holdings were not acquired to change or influence control of CalciMedica, characterizing the stake as passive.
CalciMedica, Inc. reported that it has discontinued its Phase 2 KOURAGE clinical trial after a recommendation from the study’s Independent Data Monitoring Committee. The company cited reduced planned operating expenses from stopping the trial and updated its cash outlook accordingly.
CalciMedica now expects its existing cash, cash equivalents and short-term investments to fund its current operating plan into the fourth quarter of 2026, an improvement from its prior guidance of funding into the second half of 2026. The company also reiterated standard cautionary language about forward-looking statements and referenced previously disclosed risk factors.
CalciMedica, Inc. has discontinued its Phase 2 KOURAGE clinical trial of Auxora in patients with Stage 2 or Stage 3 acute kidney injury with associated acute hypoxemic respiratory failure. The move follows a safety-related recommendation from the trial’s Independent Data Monitoring Committee, which believes the study design and patient enrollment criteria should be reevaluated.
The company states there were no deaths assessed as related to Auxora or placebo, and no serious adverse events triggered expedited U.S. Food and Drug Administration reporting. CalciMedica will conduct a comprehensive review of the unblinded data to understand how baseline characteristics, disease severity and concomitant therapies influenced outcomes and to determine how future clinical evaluation of Auxora in AKI may proceed. The FDA has been notified, and investigators will follow all enrolled patients for 90 days.
CalciMedica, Inc. filed its Q3 2025 report, detailing ongoing operating losses and liquidity pressure. The company reported a net loss of $7.804 million for the quarter and $18.802 million for the nine months ended September 30, 2025. Operating expenses were $5.618 million in Q3, led by research and development of $3.851 million.
As of September 30, 2025, cash and cash equivalents were $5.470 million and short‑term investments were $8.614 million. Management states there is substantial doubt about the company’s ability to continue as a going concern. The balance sheet shows a stockholders’ deficit of $268 thousand, a promissory note at fair value of $8.900 million, and a warrant liability of $2.600 million.
The company funded $10.0 million under a loan on February 28, 2025, bearing interest at the greater of 5.00% + prime or 12.75%, maturing on September 1, 2028. During 2025, it raised additional equity via its ATM program, selling 760,130 shares for net proceeds of $1.761 million through September 30. Shares outstanding were 14,409,431 as of November 6, 2025.
CalciMedica, Inc. (CALC) furnished an 8-K announcing it issued a press release with financial results for the fiscal quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The company stated the information under Item 2.02, including Exhibit 99.1, is furnished, not filed under the Exchange Act and is not subject to Section 18 liabilities. It will not be incorporated by reference into other filings except if specifically referenced.
CalciMedica, Inc. (CALC) increased its at‑the‑market capacity to $9,700,000. The company filed a prospectus supplement to raise the maximum aggregate offering price of common stock that may be issued under its at‑the‑market offering agreement with H.C. Wainwright & Co.
The prior limit under the program was $4,450,000, as referenced in an earlier supplement. A legal opinion covering the $9,700,000 of common stock was included as Exhibit 5.1.
CALC filed a prospectus supplement for its at-the-market program, stating it may offer and sell shares of common stock with an aggregate offering price of up to $9,700,000 from time to time through H.C. Wainwright & Co. as sales agent under Form S-3 General Instruction I.B.6.
The filing cites a public float of approximately $36.3 million, based on 14,399,531 shares outstanding and 10,146,506 shares held by non‑affiliates at a $3.58 closing price on September 9, 2025. The company has sold $2.3 million of securities under I.B.6 during the prior 12 months. The stock last traded at $3.03 on November 5, 2025. Pursuant to I.B.6, public primary sales cannot exceed one‑third of the public float in any 12‑month period while float remains below $75.0 million.